SMRI: A New Method for siRNA Design for COVID-19 Therapy

Area of Science:

• Biotechnology
• Virology
• Genetics

Background:

• COVID-19, caused by SARS-CoV-2, became a global pandemic with limited treatment options by March 2020.
• Ribonucleic Acid interference (RNAi) is a gene-silencing technology effective against RNA viruses.
• Developing efficient and safe RNAi-based therapies for COVID-19 is crucial.

Purpose of the Study:

• To introduce a novel, efficient small interfering RNA (siRNA) design method, Simple Multiple Rules Intelligent Method (SMRI), for COVID-19 treatment.
• To develop a new model (BPTC) and index (SER) for predicting siRNA silencing efficiency and filtering candidates.
• To identify high-efficiency, safe siRNAs targeting the SARS-CoV-2 spike protein gene.

Main Methods:

• Developed the Base Preference and Thermodynamic Characteristic (BPTC) model to predict siRNA efficacy.
• Introduced the siRNA Extended Rules (SER) index for screening and filtering siRNAs.
• Applied the SMRI method to design siRNAs targeting the SARS-CoV-2 spike (S) gene.
• Ensured designed siRNAs have at least three base mismatches with human genes for safety.

Main Results:

• The SMRI method demonstrated robustness and efficiency compared to traditional statistical indicators.
• Candidate siRNAs designed by SMRI showed predicted interference efficiency comparable to mainstream algorithms.
• SMRI successfully identified five candidate siRNAs with high efficacy, ease of synthesis, and enhanced safety profiles.
• The method ensured designed siRNAs avoided off-target effects on human genes.

Conclusions:

• The SMRI method offers a new, efficient, and safe approach for designing siRNAs against SARS-CoV-2.
• This RNAi-based strategy provides a potential therapeutic solution for COVID-19 with small dosage and long efficacy.
• The developed BPTC model and SER index contribute to more accurate siRNA design and screening.